UBS increased its holding in BlackRock's iShares Bitcoin Trust (IBIT) to about 2.5 million shares valued near $90 million by June 30, 2026, a 230% rise in value from the start of the year. The share count grew 355% from roughly 549,000 shares at the end of 2025, indicating UBS or its clients significantly expanded exposure despite IBIT's market price falling nearly 33% in the same period. The filing does not clarify if the shares belong directly to UBS or its clients, nor does it suggest UBS plans to become a Bitcoin custodian. This move reflects UBS's ongoing efforts to offer regulated crypto investment options, particularly for wealthy clients, through U.S.-listed Bitcoin ETFs that provide exposure without direct crypto custody. UBS's Bitcoin ETF stake remains a small fraction of its total assets under management, highlighting a cautious but growing interest in digital assets.
AT&T has been upgraded to a Strong Buy rating due to its improved free cash flow guidance, now expected to reach around $18 billion by 2026. The company shows strong pricing power and accelerating earnings, supported by rising wireless average revenu...
Jefferies has reaffirmed its 'buy' rating on Prudential PLC, highlighting management's confidence in demand for its Hong Kong insurance products. Prudential reported a 9% rise in adjusted operating profit before tax to $1.81 billion and a 10% increas...
OpenAI announced it will start displaying ads on its ChatGPT Free and Go subscription tiers in India, where it has over 100 million weekly active users. The company plans to feature ads from 50 brands and launch an ad manager next month to help marke...
Moonwell, a decentralized lending protocol on Base, has frozen borrowing in its MAMO Core Market by reducing the borrow cap to 1 wei after an attacker exploited low liquidity in the MAMO token. The attacker manipulated MAMO's price, using inflated co...
In 2026, both CVS and Intel showed strong turnaround results but faced stock sell-offs for different reasons. Intel's decline stems from doubts about its 18A manufacturing roadmap and competitive pressure, while CVS's drop relates to a cautious 2027 ...
